论文部分内容阅读
目的:研究变应性鼻炎(AR)和变应性鼻炎合并支气管哮喘(AR+BA)患者特异性免疫治疗(SIT)的疗效。方法:全部患者分为AR组(32例)和AR+BA组(32例),另设健康对照组32例。对前两组患者的变应原、症状体征评分、疗效情况进行分析并抽取三组血清行sIgE、IL-4检测。应用SPSS 13.0软件包进行t检验、χ2检验。结果:AR组和AR+BA组患者主要变应原为粉尘螨和屋尘螨,行SIT前后症状体征有明显改善(P<0.05);总有效率均为100%,但AR组疗效优于AR+BA组(P<0.05);三组血清sIgE、IL-4比较,AR组和AR+BA组浓度值均高于健康对照组(P<0.01),AR组浓度值低于AR+BA组(P<0.01)。结论:SIT对AR、AR+BA是一种安全有效的治疗方法,但不同疾病对SIT的反应不同,推荐长疗程治疗。
Objective: To investigate the efficacy of specific immunotherapy (SIT) in patients with allergic rhinitis (AR) and allergic rhinitis complicated with bronchial asthma (AR + BA). Methods: All the patients were divided into AR group (32 cases) and AR + BA group (32 cases), and another 32 healthy control subjects. The allergens, symptoms and signs score, the curative effect of the two groups were analyzed and three groups of serum sIgE and IL-4 were detected. SPSS 13.0 software package for t test, χ2 test. Results: The main allergens in AR and AR + BA groups were Dust mite and house dust mite. The symptoms and signs before and after SIT were significantly improved (P <0.05); the total effective rate was 100% AR + BA group (P <0.05). The levels of serum sIgE and IL-4 in the three groups were significantly higher than those in the healthy control group (P <0.01) Group (P <0.01). Conclusion: SIT is a safe and effective treatment for AR and AR + BA. However, the response of SIT to different diseases is different, and a long course of treatment is recommended.